BAY-41-8543 is a novel and potent NO-independent guanylyl cyclase stimulator. BAY 41-8543 is a heme-dependent sGC stimulator that raises the activity of recombinant sGC in a dose-dependent manner.
Physicochemical Properties
| Molecular Formula | C21H21FN8O |
| Molecular Weight | 420.44 |
| Exact Mass | 420.182 |
| Elemental Analysis | C, 59.99; H, 5.03; F, 4.52; N, 26.65; O, 3.81 |
| CAS # | 256498-66-5 |
| Related CAS # | 256498-66-5 |
| PubChem CID | 9953906 |
| Appearance | White to off-white solid powder |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 599.7±50.0 °C at 760 mmHg |
| Flash Point | 316.5±30.1 °C |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.762 |
| LogP | -1.16 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 31 |
| Complexity | 584 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | FC1=C(C=CC=C1)CN2N=C(C3=CC=CN=C32)C4=NC(N)=C(C(N)=N4)N5CCOCC5 |
| InChi Key | AQYFUZRYBJBAGZ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C21H21FN8O/c22-15-6-2-1-4-13(15)12-30-21-14(5-3-7-25-21)16(28-30)20-26-18(23)17(19(24)27-20)29-8-10-31-11-9-29/h1-7H,8-12H2,(H4,23,24,26,27) |
| Chemical Name | 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5-morpholin-4-ylpyrimidine-4,6-diamine |
| Synonyms | BAY-41-8543; BAY418543; BAY41-8543; UNII-323T2C09SG |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | BAY 41-8543 (10-100 μg/kg; IV) increases cardiac output, produces dose-dependent reductions in systemic arterial pressure, and causes smaller drops in pulmonary arterial pressure[1]. (0.003, 0.01, 0.03, 0.1, and 0.3 mg/kg; iv) causes a dose-dependent and sustained drop in blood pressure in anaesthetized rats. Beyond the 30-minute observation period, BAY 41-8543 continues to lower blood pressure. BAY 41-8543 (0.1, 0.3, and 1.0 mg kg; oral) has the highest potential to lower blood pressure. The maximum dosages of BAY41-8543 have blood pressure-lowering effects that last longer than the 120-minute observation period[2]. BAY 41-8543 (3 mg/kg; p.o.; twice daily; for 5 weeks) totally blocks the development of the rise in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 significantly raises survival[2]. |
| Animal Protocol |
Adult male Sprague-Dawley rats weighing 325-450 g 10, 30, and 100 μg/kg IV |
| References |
[1]. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol. [2]. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol. 2002 Jan;135(2):344-55. |
| Additional Infomation | BAY-41-8543 is a pyrazolopyridine. |
Solubility Data
| Solubility (In Vitro) |
DMF: ~16.7 mg/mL (~39.7 mM) Ethanol: ~1 mg/mL (2.4 mM) DMSO: < 1 mg/mL |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3785 mL | 11.8923 mL | 23.7846 mL | |
| 5 mM | 0.4757 mL | 2.3785 mL | 4.7569 mL | |
| 10 mM | 0.2378 mL | 1.1892 mL | 2.3785 mL |